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Introduction
ECCO2R (extracorporeal dioxide carbon removal) is an
extracorporeal decarboxylation technology described in
19781. Physiological studies showed that 50% of produced
CO2 were eliminated2. Potential indications are: ultra-pro-
tective mechanical ventilation (MV) for acute respiratory
distress syndrome (ARDS)3 and hypercapnic patients at
risk of failure of noninvasive ventilation (NIV)4. Because of
the lack of scientific evidence, ECCO2R is not available in
the USA. Several trials are currently conducted in Europe.
Objectives
To assess the use of ECCO2R in France.
Methods
This retrospective, observational study was performed in
French intensive care units (ICUs) from January 2010 to
January 2015. A phone interview was conducted with
French ICUs affiliated to national societies and public and
private hospitals registries. Data recorded were the follow-
ing: use and indications of ECCO2R, type of ECCO2R,
number of treated patients during the study period, com-
plications associated with the technique, satisfaction rates
(in term of efficacy, tolerance and global) based on a scale
(0 to 10), and concomitant use of ECMO in the unit.
Results
222 French ICUs were contacted (52 medical, 20 surgical,
132 polyvalent, 3 cardio-thoracic, 6 paediatric and 2 neu-
rosurgical ICU). Only 3 refused to participate. Thirty-three
(15%) ICU had used ECCO2R at least once in the past five
years, in 292 patients. Most frequent devices used were:
iLA® (Novalung) (63%) and Hemolung® (Alung) (36%).
The median number per ICU of treated patients was
3[1-7]. The most frequent indication was ultra-protective
ventilation for ADRS (54%). Other indications were: failure
of NIV during COPD exacerbation (30%), weaning from
invasive MV in COPD patients (12%) and miscellaneous
(4%). Among ICUs using ECCO2R, 22 (67%) reported at
least one complication. The most frequent complications
were bleeding (45%) and membrane failure (18%). Satisfac-
tion rates were: in term of decarboxylation 7.9 ± 2.4; toler-
ance 6.9 ± 2.6; overall satisfaction 6.8 ± 2.2. Twenty-one
(63%) of the 33 ICUs using ECCO2R, also used ECMO.
The main reasons for not using ECCO2R were the lack of
trained staff, unavailability of the device and the lack of
scientific evidence (in respectively 56.5%, 38% and 19%).
Conclusions
These preliminary results show that ECCO2R is not widely
used in French ICUs. The lack of strong scientific data on
outcome is probably the main reason behind the limited
use of ECCO2R. French studies currently in progress will
help define indications of ECCO2R and impact on
outcome.
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